- Home
- ALLR vs GLMD Comparison
ALLR vs GLMD Comparison
Compare ALLR & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- GLMD
- Stock Information
- Founded
- ALLR 2004
- GLMD 2000
- Country
- ALLR United States
- GLMD Israel
- Employees
- ALLR N/A
- GLMD N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- GLMD Health Care
- Exchange
- ALLR Nasdaq
- GLMD Nasdaq
- Market Cap
- ALLR 4.7M
- GLMD 4.6M
- IPO Year
- ALLR N/A
- GLMD 2014
- Fundamental
- Price
- ALLR $1.05
- GLMD $2.90
- Analyst Decision
- ALLR
- GLMD
- Analyst Count
- ALLR 0
- GLMD 0
- Target Price
- ALLR N/A
- GLMD N/A
- AVG Volume (30 Days)
- ALLR 2.6M
- GLMD 41.9K
- Earning Date
- ALLR 03-07-2025
- GLMD 11-14-2024
- Dividend Yield
- ALLR N/A
- GLMD N/A
- EPS Growth
- ALLR N/A
- GLMD N/A
- EPS
- ALLR N/A
- GLMD N/A
- Revenue
- ALLR N/A
- GLMD N/A
- Revenue This Year
- ALLR N/A
- GLMD N/A
- Revenue Next Year
- ALLR N/A
- GLMD N/A
- P/E Ratio
- ALLR N/A
- GLMD N/A
- Revenue Growth
- ALLR N/A
- GLMD N/A
- 52 Week Low
- ALLR $0.90
- GLMD $2.56
- 52 Week High
- ALLR $288.00
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- ALLR 47.15
- GLMD 45.51
- Support Level
- ALLR $0.96
- GLMD $2.84
- Resistance Level
- ALLR $1.72
- GLMD $3.01
- Average True Range (ATR)
- ALLR 0.17
- GLMD 0.22
- MACD
- ALLR 0.01
- GLMD -0.02
- Stochastic Oscillator
- ALLR 13.99
- GLMD 13.41
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.